XML 53 R45.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2012 Targets | Jan. 31, 2012 Targets | Dec. 31, 2013 Product | Dec. 31, 2012
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Deferred revenue |  |  | $ 2,282,000 | $ 2,304,000
Shire AG [Member] |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Aggregate number of gene targets |  | 7 |  |
Number of initial gene targets |  | 4 |  |
Number of gene targets | 5 |  |  |
Number of additional gene targets | 2 |  |  |
Research program to develop laboratory research reagents |  |  | 6 years |
Upfront license fee |  | 13,000,000 |  |
Potential amount to be funded for certain Shire milestones |  |  | 213,500,000 |
Potential amount eligible to receive for certain Shire milestones |  |  | 33,500,000 |
Potential amount to be funded for achievement of specified commercialization and sales milestones |  |  | 180,000,000 |
IND or CTA submission amount |  |  | 8,500,000 |
Number of products approved |  |  | 0 |
Royalty revenue |  |  | 0 |
Deferred revenue |  |  | 8,900,000 |
Collaboration agreement related costs and expenses |  |  | $ 14,200,000 | $ 7,700,000

X
- Definition Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate number of gene targets. + References No definition available. + Details
Name: | sgmo_AggregateNumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement related costs and expenses. + References No definition available. + Details
Name: | sgmo_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfAdditionalGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of initial gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfInitialGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | sgmo_UpfrontLicenseFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration